2022
DOI: 10.3390/jcm11113247
|View full text |Cite
|
Sign up to set email alerts
|

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Use for Atherogenic Dyslipidemia in Solid Organ Transplant Patients

Abstract: Dyslipidemia is a widespread risk factor in solid organ transplant patients, due to many reasons, such as the use of immunosuppressive drugs, with a consequent increase in cardiovascular diseases in this population. PCSK9 is an enzyme mainly known for its role in altering LDL levels, consequently increasing cardiovascular risk. Monoclonal antibody PCSK9 inhibitors demonstrated remarkable efficacy in the general population in reducing LDL cholesterol levels and preventing cardiovascular disease. In transplant p… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 113 publications
0
1
0
Order By: Relevance
“…To date, there is little evidence in transplant recipients [ 147 ], but PCSK9 inhibitors have been shown to be a very effective treatment for dyslipidemia, with a reported reduction in LDL values of up to 50% [ 148 ]. Moreover, PCSK9 seems to be safe in these patients because they are not involved in CYP3A4 or P-gp metabolism; however, reductions in CsA and sirolimus levels have been reported, without negative effects on rejection [ 148 ].…”
Section: Management Of Dyslipidemia In Transplant Recipientsmentioning
confidence: 99%
“…To date, there is little evidence in transplant recipients [ 147 ], but PCSK9 inhibitors have been shown to be a very effective treatment for dyslipidemia, with a reported reduction in LDL values of up to 50% [ 148 ]. Moreover, PCSK9 seems to be safe in these patients because they are not involved in CYP3A4 or P-gp metabolism; however, reductions in CsA and sirolimus levels have been reported, without negative effects on rejection [ 148 ].…”
Section: Management Of Dyslipidemia In Transplant Recipientsmentioning
confidence: 99%